AKT1 and neoplasm: A combination of PD-1 blockade with Akt-mTOR inhibition reduced the tumor growth, accompanied by a decrease in Foxp+ Treg cells and an increase in CD3+ T cells, indicating immune activation (Zhao et al., 2019).